Amendment to Share Options

RNS Number : 6113I

Yourgene Health PLC

12 August 2019

 

Yourgene Health plc

("Yourgene" or the "Company")

Amendment to Share Options

Manchester, UK - 12 August 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces an amendment to existing share options held by certain Directors of the Company.

The existing share options below (issued 19 March 2014) have had their performance conditions modified so as to be aligned with other senior incentives:

Name	Existing options subject to amendment	Total number of options held
Adam Reynolds	591,666	591,666
Nick Mustoe	591,666	591,666

The exercise price of these options has not been changed and remains at 10 pence.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For more information, please contact:
Yourgene Health plc				Tel: [phone]
Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing
[e-mail]
Cairn Financial Advisers LLP (Nomad)				Tel: [phone]
Liam Murray / James Caithie / Ludovico Lazzaretti
Stifel Nicolaus Europe Limited (Corporate Broker)				Tel: [phone]
Nicholas Moore / Matthew Blawat / Ben Maddison
Walbrook PR Ltd (Media and Investor Relations)	Tel: [phone] or [e-mail]
Paul McManus / Lianne Cawthorne / Anna Dunphy		Mob: [phone] /
			07876 741 001

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science. 

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

 

 

END

 

 

DSHZKLFBKVFBBBF